Actually the SAVA results are in a class above ANYTHING AVXL has put out for AD. SAVA actually improved test scores. In an open label, non PET Scan trial of over 30 patients only 2 scored better than baseline in the Anavex trial. Apparently nearly all 50 did in the SAVA trial. Now I'm not predicting share prices moving forward but SAVA has clearly demonstrated better results at this point. As for Rett, hopefully Anavex is successful. They have produced solid results in a very small trial but if you're going to argue FDA processes put Anavex in the lead over SAVA then surely you can see why one would argue that Anavex is over a year behind Neuren for Rett. Once again, not saying Anavex won't be successful or stock won't be a winner or that SAVA might not be overpriced or anything like that, but currently SAVA has laid a KO punch to what Anavex has produced for AD IMO. Many of these AD small cap plays have run this week, likely based off SAVA's coattails. JMHO